Old Web
English
Sign In
Acemap
>
authorDetail
>
Jamie N. Connarn
Jamie N. Connarn
Celgene
Medicine
Pharmacokinetics
Pharmacology
Cancer research
Paclitaxel
4
Papers
17
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment
2019
Yan Li
Jamie N. Connarn
Jian Chen
Zeen Tong
Maria Palmisano
Simon Zhou
Show All
Source
Cite
Save
Citations (4)
Sotatercept safety and effects on hemoglobin, bone, and vascular calcification
2019
Kidney International Reports
Daniel W. Coyne
Hem Nalini Singh
William Smith
Ana Carolina Giuseppi
Jamie N. Connarn
Matthew L. Sherman
Frank Dellanna
Hartmut H. Malluche
Keith A. Hruska
Show All
Source
Cite
Save
Citations (6)
Population Pharmacokinetics of Lenalidomide in Healthy Volunteers and Patients With Hematologic Malignancies
2018
Clinical pharmacology in drug development
Jamie N. Connarn
Renfang Hwang
Yue Gao
Maria Palmisano
Nianhang Chen
Show All
Source
Cite
Save
Citations (5)
A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST).
2018
Journal of Clinical Oncology
Michael S. Gordon
Geoffrey I. Shapiro
John Sarantopoulos
Dejan Juric
Brian Lu
Peng Chen
Jamie N. Connarn
Yvan Le Bruchec
R. Donald Harvey
Show All
Source
Cite
Save
Citations (2)
1